Search Results
DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvement
DESTINY-Breast04: T-DXd for patients with HER2-low mBC
Clinical outcomes in women with metastatic HER2-low breast cancer in the real world
Biological behaviour of HER2-low BC is dependent on HR expression
ADCs for HER2+ and HER2-low breast cancer
The latest news on the management of breast cancer patients with brain metastases
Highlights from SABCS 2021: T-DXd, KEYNOTE-355, PADA-1 & EMERALD
DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer
Final results from DESTINY-CRC01: T-Dxd in HER2-expressing mCRC
HER2-Low Expression in Breast Cancer: Opportunities for Expanding Treatment Benefit to More Patients
Her2 Low Breast Cancer
2021 SABCS What Changes Monday Morning? HER2+ Breast Cancer Panel Discussion
